Who are the global manufacturers of nivolumab?

Global Manufacturers of Nivolumab

Nivolumab, also known as Opdivo, is a monoclonal antibody medication used to treat various types of cancer. The global manufacturers of nivolumab include:

Bristol Myers Squibb (BMS)

[1] BMS, headquartered in New York City, is the primary manufacturer and marketer of nivolumab worldwide. BMS has obtained regulatory approvals for nivolumab in over 60 countries, including the US, EU, and Japan.

Other Manufacturers and Biosimilars

While BMS has exclusive rights to nivolumab in most countries, some manufacturers have developed biosimilars or generic versions of the drug. These include:

* Sandoz, a Novartis subsidiary, has received approval for a nivolumab biosimilar in several countries, including Japan and several EU nations.
* Amgen, a US-based biotech company, has launched a nivolumab biosimilar in the US under the brand name Mvasi.
* Samsung Bioepis, a Korean-Swedish joint venture, has also developed a nivolumab biosimilar, which has been approved in several countries, including Australia and EU nations.

Regulatory Approvals and Exclusivity

Nivolumab's regulatory approvals and exclusivity are subject to change based on patent expirations, biosimilar approvals, and marketing authorizations. According to DrugPatentWatch.com [2], nivolumab's US patent expires in 2025, while the EU patent expires in 2028.

Sources

[1] Bristol Myers Squibb. (2022). About Opdivo (Nivolumab).

[2] DrugPatentWatch.com. (2023). Nivolumab patents.

External Links

* BMS Website: www.bms.com
* Sandoz Website: www.sandoz.com
* Amgen Website: www.amgen.com
* Samsung Bioepis Website: www.samsungbioepis.com
* DrugPatentWatch.com: www.drugpatentwatch.com